VVUS stock forecast
Our latest prediction for VIVUS, Inc.'s stock price was made on the Nov. 6, 2018 when the stock price was at 3.98$.
In the short term (2weeks), VVUS's stock price should outperform the market by 4.29%. During that period the price should oscillate between -8.34% and +15.43%.
In the medium term (3months), VVUS's stock price should outperform the market by 3.29%. During that period the price should oscillate between -19.32% and +38.89%.Get email alerts
About VIVUS, Inc.
VIVUS, Inc. engages in the development and commercialization of novel therapeutic products. The firm's products are indicated for the treatment of obese and overweight patients, exocrine pancreatic insufficiency, and erectile dysfunction. Its products include PANCREAZE, Qsymia, and STENDRA/SPEDRA. The company was founded by Virgil A. Place in April 16, 1991 and is headquartered in Campbell, CA.
At the moment the company generates 57M USD in revenues.
On its last earning announcement, the company reported a loss of -4.03$ per share.
The book value per share is -2.62$
Three months stock forecastNov. 6, 2018
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|